Roche NimbleGen Announces Frank Pitzer as New CEO
News Mar 26, 2010
Roche NimbleGen has announced that Frank Pitzer has been appointed as CEO. Dr. Pitzer’s extensive background and experience of over eight years at Roche will be instrumental in guiding the company through its next stage of growth.
With his successful track record in several key management positions within Roche Diagnostics, he brings a wealth of organizational, commercial, and relevant operating experience in key areas impacting the genomics and life science industry.
Dr. Pitzer most recently served as Head of Divisional Quality and Regulatory Affairs reporting directly to the CEO of Roche Diagnostics and was also an active member of the Diagnostics Executive Committee (DEC). In addition to his extensive management experience and background at Roche, Dr. Pitzer brings a broad scientific perspective having earned a PhD in Biology from Max Planck Institute for Biochemistry.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.